[HTML][HTML] Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines …
Since 2021, 2 B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
(CAR-T) therapies—idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta …
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
M Engelhardt, KM Kortüm, H Goldschmidt… - …, 2024 - pmc.ncbi.nlm.nih.gov
Multiple myeloma (MM) is a heterogeneous disease with survival ranging from months to
decades. The goal of 'cure'remains elusive for most patients, but has been shown to be …
decades. The goal of 'cure'remains elusive for most patients, but has been shown to be …
Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma
The literature is limited regarding outcomes in older adults and frail patients receiving BCMA-
directed chimeric antigen receptor T cell therapy (CAR-T) for relapsed or refractory multiple …
directed chimeric antigen receptor T cell therapy (CAR-T) for relapsed or refractory multiple …
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell …
ZE Walton, MJ Frigault, MV Maus - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Chimeric antigen receptor (CAR) T cells have revolutionized the treatment of
multiple hematologic malignancies. Engineered cellular therapies now offer similar hope to …
multiple hematologic malignancies. Engineered cellular therapies now offer similar hope to …
[PDF][PDF] Challenges in Multiple Myeloma Therapy in Older and Frail Patients
A Aureli, B Marziani, T Sconocchia, G Pasqualone… - 2025 - preprints.org
Every year, more than 150,000 cases of multiple myeloma (MM) are diagnosed worldwide,
and over 100,000 deaths caused by this malignancy are recorded. MM incidence is …
and over 100,000 deaths caused by this malignancy are recorded. MM incidence is …
Zelluläre Therapien im Alter: Everything, everywhere, all at once?
W Rösler - InFo Hämatologie+ Onkologie, 2024 - Springer
Zelluläre Therapien wie eine Stammzelltransplantation waren lange Zeit jüngeren oder
wenigen ausgewählten „fitten “älteren Patientinnen und Patienten vorbehalten. Durch die …
wenigen ausgewählten „fitten “älteren Patientinnen und Patienten vorbehalten. Durch die …